Article Details

Regeneron's Eylea beats out the competition in the US as patient demand picks back up

Retrieved on: 2021-05-06 15:31:09

Tags for this article:

Click the tags to see associated articles and topics

Regeneron's Eylea beats out the competition in the US as patient demand picks back up. View article details on hiswai:

Excerpt

In their battle for a larger piece of the macular degeneration pie, Regeneron's Eylea is edging out Roche's Lucentis in the key U.S. market. With sales ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo